Ken Griffin Coherus Bio Sciences, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 30,700 shares of CHRS stock, worth $32,235. This represents 0.0% of its overall portfolio holdings.

Number of Shares

30,700

Previous 39,200 21.68%

Holding current value

$32,235

Previous $93,000 43.01%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.58 - $2.51 $159,297 - $253,060	100,821 Added 3.68%	2,843,448 $4.92 Million
Q1 2024 May 15, 2024	BUY	$2.02 - $3.14 $1.52 Million - $2.37 Million	754,730 Added 37.97%	2,742,627 $6.55 Million
Q4 2023 Feb 14, 2024	SELL	$1.59 - $3.85 $1.07 Million - $2.59 Million	-671,820 Reduced 25.26%	1,987,897 $6.62 Million
Q3 2023 Nov 14, 2023	SELL	$3.74 - $5.45 $12.4 Million - $18.1 Million	-3,320,003 Reduced 55.52%	2,659,717 $9.95 Million
Q2 2023 Aug 14, 2023	BUY	$3.79 - $8.3 $17 Million - $37.2 Million	4,482,817 Added 299.47%	5,979,720 $25.5 Million
Q1 2023 May 15, 2023	BUY	$5.89 - $10.52 $1.08 Million - $1.93 Million	183,560 Added 13.98%	1,496,903 $10.2 Million
Q4 2022 Feb 14, 2023	BUY	$5.69 - $10.07 $6.39 Million - $11.3 Million	1,123,781 Added 592.83%	1,313,343 $10.4 Million
Q3 2022 Nov 14, 2022	BUY	$7.17 - $13.87 $1.36 Million - $2.63 Million	189,562 New	189,562 $1.82 Million
Q2 2022 Aug 15, 2022	SELL	$5.86 - $13.23 $737,996 - $1.67 Million	-125,938 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$10.92 - $16.41 $565,623 - $849,988	51,797 Added 69.86%	125,938 $1.63 Million
Q4 2021 Feb 14, 2022	SELL	$15.81 - $18.99 $1.84 Million - $2.21 Million	-116,283 Reduced 61.07%	74,141 $1.18 Million
Q3 2021 Nov 15, 2021	BUY	$12.68 - $17.79 $2.21 Million - $3.1 Million	174,046 Added 1062.68%	190,424 $3.06 Million
Q2 2021 Aug 16, 2021	SELL	$12.95 - $15.41 $5.28 Million - $6.28 Million	-407,421 Reduced 96.14%	16,378 $226,000
Q1 2021 May 17, 2021	BUY	$14.42 - $21.39 $2.94 Million - $4.36 Million	203,809 Added 92.64%	423,799 $6.19 Million
Q4 2020 Feb 16, 2021	SELL	$16.56 - $18.94 $766,330 - $876,467	-46,276 Reduced 17.38%	219,990 $3.82 Million
Q3 2020 Nov 16, 2020	BUY	$17.41 - $19.89 $1.59 Million - $1.82 Million	91,608 Added 52.45%	266,266 $4.88 Million
Q2 2020 Aug 14, 2020	SELL	$14.43 - $19.16 $2.15 Million - $2.86 Million	-149,170 Reduced 46.06%	174,658 $3.12 Million
Q1 2020 May 15, 2020	BUY	$11.67 - $22.53 $643,857 - $1.24 Million	55,172 Added 20.54%	323,828 $5.25 Million
Q4 2019 Feb 14, 2020	SELL	$16.33 - $21.37 $6.63 Million - $8.67 Million	-405,762 Reduced 60.16%	268,656 $4.84 Million
Q3 2019 Nov 14, 2019	BUY	$16.3 - $23.37 $2.81 Million - $4.02 Million	172,187 Added 34.28%	674,418 $13.7 Million
Q2 2019 Aug 14, 2019	SELL	$13.1 - $22.1 $26.3 Million - $44.4 Million	-2,009,751 Reduced 80.01%	502,231 $11.1 Million
Q1 2019 May 15, 2019	BUY	$8.38 - $15.5 $2.62 Million - $4.85 Million	313,172 Added 14.24%	2,511,982 $0
Q4 2018 Feb 14, 2019	BUY	$8.65 - $16.28 $2.3 Million - $4.34 Million	266,409 Added 13.79%	2,198,810 $19.9 Million
Q3 2018 Nov 13, 2018	SELL	$14.45 - $20.25 $2.55 Million - $3.58 Million	-176,550 Reduced 8.37%	1,932,401 $0
Q2 2018 Aug 10, 2018	BUY	$10.25 - $17.45 $4.13 Million - $7.03 Million	402,929 Added 23.62%	2,108,951 $0
Q1 2018 May 11, 2018	SELL	$9.1 - $13.7 $602,592 - $907,200	-66,219 Reduced 3.74%	1,706,022 $18.9 Million
Q4 2017 Feb 09, 2018	BUY	$8.35 - $14.4 $13.2 Million - $22.7 Million	1,579,582 Added 819.88%	1,772,241 $15.6 Million
Q3 2017 Nov 09, 2017	BUY	$11.1 - $14.5 $2.14 Million - $2.79 Million	192,659	192,659 $2.57 Million

Others Institutions Holding CHRS

# of Institutions

143

Shares Held

82.7M

Call Options Held

79.1K

Put Options Held

100K

View Full List

About Coherus BioSciences, Inc.

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $81.6M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

More about CHRS

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account